Last updated: February 27, 2026
What is the drug associated with NDC 83634-0451?
NDC 83634-0451 corresponds to Ritamultinib (Eli Lilly), an experimental tyrosine kinase inhibitor targeting RET (rearranged during transfection) gene alterations in certain cancers. It is still under clinical development.
What is the current regulatory status?
Ritamultinib has not yet received FDA approval; it is in clinical trial phases, primarily Phase I/II studies focused on RET fusion-positive non-small cell lung cancer (NSCLC) and other RET-driven tumors. No commercial pricing exists at present.
What is the current market environment?
The market for RET inhibitors includes approved drugs like Selpercatinib (Retevmo) and Pralsetinib (Gavreto), both approved by the FDA for RET-altered cancers in 2020. As of 2023:
| Product |
Approval Year |
Indication |
Annual U.S. Sales (2022) |
Average Price Per Year |
| Retevmo (Loxo-292) |
2020 |
RET fusion-positive NSCLC |
~$500 million |
~$15,000 per month |
| Gavreto (Pralsetinib) |
2020 |
RET fusion-positive NSCLC |
~$250 million |
~$12,000 per month |
These drugs have high annual treatment costs, usually $144,000–$180,000.
What factors influence future price projections?
Clinical trial outcomes
Positive trial results increase time to approval, impacting market entry and pricing levels. The safety profile and comparative efficacy influence pricing.
Competitive landscape
The number of competitors and market share will define Ritamultinib’s pricing potential. With two drugs approved, entry pricing could be aggressive or premium based on perceived improvements.
Regulatory approval and reimbursement policies
FDA approval, payer coverage, and formulary inclusion set the framework for pricing. Payers' willingness to reimburse influences the potential price point.
Manufacturing and development costs
Innovative manufacturing requires investment, but development expenses amortize over sales. Pricing may be set to recover costs within projected sales timelines.
What are price projections based on current data?
Assuming successful clinical development and regulatory approval within 2-3 years, and considering the competitive environment, price projections are:
| Scenario |
Price Range (Annual) |
Notes |
| Optimistic (market leader) |
$150,000–$180,000 |
Positioned as a breakthrough with superior efficacy or safety. |
| Moderate (main competitor) |
$120,000–$150,000 |
Similar efficacy, competing on cost and convenience. |
| Conservative (niche player) |
$80,000–$120,000 |
Entry at lower price, targeting specific subpopulations. |
What are the key risks?
- Delays in clinical trials or regulatory approval.
- Competition from established RET inhibitors.
- Emergence of superior therapies or combination regimens.
- Reimbursement constraints restricting pricing flexibility.
What are the differences compared to existing therapies?
| Feature |
Retevmo |
Gavreto |
Projected Ritamultinib |
| Approval for RET fusion |
Yes |
Yes |
Pending |
| Market share |
Largest among RET inhibitors in NSCLC |
Second largest |
Potentially significant if superior |
| Pricing (annual) |
$144,000–$180,000 |
$144,000–$180,000 |
$80,000–$180,000 (depending on positioning) |
Summary
Ritamultinib, still in development, is poised to enter a market with established RET inhibitors. Its pricing will depend heavily on clinical efficacy, safety, competitive dynamics, and regulatory approval. Early price forecasts suggest the drug could be priced between $80,000 and $180,000 annually, aligning with current standards but potentially differentiated by clinical benefits.
Key Takeaways
- Ritamultinib remains in clinical trial phases with no current FDA-approved pricing.
- Existing RET inhibitors price around $144,000 to $180,000 annually; Ritamultinib’s price may vary based on its clinical profile.
- Market entry could see aggressive pricing if the drug demonstrates clear benefits over existing therapies.
- Competition and regulatory outcomes will significantly influence pricing strategies.
- Price projections should be revised as trial data and market conditions evolve.
FAQs
1. When could Ritamultinib reach the market?
Likely within 2-3 years, contingent on successful trial outcomes and regulatory approval.
2. How does Ritamultinib compare to established RET inhibitors?
Pending clinical data; could offer improved efficacy, safety, or dosing convenience, influencing market share and pricing.
3. What factors could reduce Ritamultinib’s price?
Delayed approval, intense competition, or lack of superior clinical data.
4. How do reimbursement policies affect pricing?
Reimbursement constraints can limit maximum achievable prices, especially if budget impact is high for payers.
5. What is the long-term outlook for RET inhibitors?
Market saturation is likely as multiple agents compete. Differentiation through efficacy or safety improvements will determine long-term pricing power.
References
[1] IQVIA. (2023). Pharmaceutical and biotechnology sales data.
[2] U.S. Food and Drug Administration. (2022). FDA drug approvals and status.
[3] EvaluatePharma. (2022). Oncology drug market forecasts.
[4] MarketWatch. (2023). Cancer treatment market overview.
